Activity Overview
This online, on-demand virtual symposium brings together renowned experts in neurofibromatosis type 1–associated plexiform neurofibromas (NF1-PNs). In this educational program, these experts use interactive case-based discussions and evidence-informed peer exchanges to address key decision points in diagnosis, targeted therapy selection, adverse event management, and longitudinal care coordination—with the goal of reducing practice variability and empowering community clinicians to deliver timely, personalized care for patients with NF1-PNs
This educational activity is an archive of the live presentation held on August 14, 2026.
Target Audience
This educational program is primarily directed toward community-based oncologists, nurses, NPs/APPs, and other health care professionals involved in the treatment of NF1-PNs.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Apply guideline-based diagnostic criteria to improve accurate identification, classification, and referral of patients with NF1-PNs
- Evaluate emerging clinical trial data on targeted therapies, including MEK inhibitors, to inform evidence-based treatment selection for patients with NF1-PNs
- Integrate patient-specific factors to develop individualized management plans for patients with NF1-PNs
- Identify, monitor, and manage adverse events associated with targeted therapies for NF1-PNs within real-world practice settings
Daniela A. Bota, MD, PhD
Professor, Neurology
Director, UCI Alpha Clinic
Medical Director, Comprehensive Brain Tumor Program
University of California, Irvine
Irvine, CA
Disclosures: Daniela A. Bota, MD, PhD, has no relevant financial relationships with ineligible companies
Kurt C. Demel, MD, MBA
Staff Physician
Department of Hematology/Oncology
HealthPartners/Regions Hospital
St Paul, MN
Disclosures: Kurt C. Demel, MD, MBA, has no relevant financial relationships with ineligible companies
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This accredited continuing education activity was planned in accordance with the ACCME Standards for Integrity and Independence to ensure balance, objectivity, independence, and scientific rigor. Faculty were instructed to use generic names when possible and to base recommendations on the best available evidence. Proprietary product names may be referenced in clinical discussion for educational purposes only and do not imply endorsement.
This activity may include discussion of investigational, unapproved, or off‑label uses of drugs or devices. Learners are advised to consult prescribing information for products discussed. Content is provided for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Learners are encouraged to critically evaluate the information presented and apply their own clinical judgment.
The views expressed are those of the individual faculty members and do not necessarily reflect the views of the accredited provider or any entity providing commercial support.
This activity may have used AI-assisted tools to support educational development. All content was reviewed and approved by qualified faculty or planners. The accredited provider retains full responsibility for accuracy, balance, and independence.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
